Processing

Please wait...

Settings

Settings

Goto Application

1. AR081797 - DERIVADOS DE PIRROLIDINONA HETEROAROMATICAS FUSIONADAS, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y USO DE LAS MISMAS PARA TRATAR AFECCIONES DEL SISTEMA INMUNE Y LA INFLAMACION

Office
Argentina
Application Number P100104923
Application Date 22.12.2010
Publication Number 081797
Publication Date 24.10.2012
Publication Kind A1
IPC
C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/437
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
CPC
A61K 31/437
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/527
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
527spiro-condensed
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Applicants TAKEDA PHARMACEUTICAL COMPANY LIMITEDTAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors YASUYOSHI ARIKAWAYASUYOSHIARIKAWA
VICTORIA FEHERVICTORIAFEHER
BETTY LAMBETTYLAM
ZHE NIEZHENIE
QING DONGQINGDONG
BENJAMIN JONESBENJAMINJONES
CHRISTOPHER SMITHCHRISTOPHERSMITH
MASASHI TAKAHASHIMASASHITAKAHASHI
Priority Data 61/289969 23.12.2009 US
61/386964 23.12.2009 US
Title
(ES) DERIVADOS DE PIRROLIDINONA HETEROAROMATICAS FUSIONADAS, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y USO DE LAS MISMAS PARA TRATAR AFECCIONES DEL SISTEMA INMUNE Y LA INFLAMACION
Abstract
(ES) Reivindicación 1: Un compuesto de fórmula (1), o su sal aceptable para uso farmacéutico, donde: G se selecciona de N y C(R5); L1 y L2 se seleccionan cada uno de ellos independientemente de NH y un enlace; R1 y R2 se seleccionan cada uno de ellos independientemente de hidrógeno, halo, alquilo C1-3, y haloalquilo C1-3, o R1 y R2, junto con el átomo al cual están unidos, forman un cicloalquilo C3-6; R3 se selecciona de alquilo C2-6, cicloalquilo C3-8, heterocicloalquilo C2-5, y heteroarilo C1-9, cada uno opcionalmente sustituido con uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -NO2, -CN, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, haloalquenilo C2-6, haloalquinilo C2-6, R6, y R7; R4 se selecciona de cicloalquilo C3-8, heterociclilo C2-5, arilo C6-14 y heteroarilo C1-9, cada uno opcionalmente sustituido con uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, haloalquenilo C2-6, haloalquinilo C2-6, R6, y R7; R5 se selecciona de hidrógeno, halo, OH, CN, alquilo C1-4, heterociclilo C2-5, heteroarilo C1-5, y R6, donde el resto heterociclilo tiene 3 a 6 átomos del anillo y el resto heteroarilo tiene 5 ó 6 átomos del anillo, y los restos heterociclilo y heteroarilo están cada uno de ellos opcionalmente sustituidos con uno a cuatro sustituyentes seleccionados independientemente de halo, NO2, -CN, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, haloalquenilo C2-4, haloalquinilo C2-4, R6, y R7; cada R6 se selecciona independientemente de OR7, -N(R7)R8, -NR7C(O)R8, -C(O)R7, -C(O)OR7, -C(O)N(R7)R8, -C(O)N(R7)OR8, -C(O)N(R7)S(O)2R8, -N(R7)S(O)2R8, -S(O)nR7, y -S(O)2N(R7)R8; cada R7 y R8 se selecciona independientemente de hidrogeno o de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6-(CH2)m-, aril C6-14-(CH2)m-, heterociclilo C2-5-(CH2)m-, y heteroaril C1-9-(CH2)m-, cada uno de ellos opcionalmente sustituido con uno a cinco sustituyentes independientemente seleccionados de halo, oxo, NO2, -CN, alquilo C1-6, haloalquilo C1-6 y R9; cada R9 se selecciona independientemente de OR10, -N(R10)R11, -N(R10)C(O)R11, -C(O)R10, -C(O)OR10, -C(O)N(R10)R11, -C(O)N(R7)OR8, -C(O)N(R10)S(O)2R11, -NR10S(O)2R11, -S(O)nR10, y -S(O)2N(R10)R11; cada R10 y R11 se selecciona independientemente de hidrógeno y alquilo C1-6; cada n se selecciona independientemente de 0, 1 y 2; y cada m se selecciona independientemente de 0, 1, 2, 3, y 4; donde cada uno de los restos heteroarilo antes mencionados tiene uno a cuatro heteroátomos seleccionados independientemente de N, O, y S, y cada uno de los restos heterociclilo antes mencionados está saturado o parcialmente insaturado y tiene uno o dos heteroátomos independientemente seleccionados de N, O y S.
Related patent documents
VNVN1201202064This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
KEKEP2012001594This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
MXMX/a/2012/007402This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
GE12794/1This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
GE12794This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
CO12121953This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
CRCR2012-000392This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
UAa201207806This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.